Cost Management Insights: SG&A Expenses for AbbVie Inc. and Sarepta Therapeutics, Inc.

SG&A Expenses: AbbVie vs. Sarepta's Strategic Approaches

__timestampAbbVie Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014772400000049315000
Thursday, January 1, 2015638700000075043000
Friday, January 1, 2016585500000083749000
Sunday, January 1, 20176275000000122682000
Monday, January 1, 20187399000000207761000
Tuesday, January 1, 20196942000000284812000
Wednesday, January 1, 202011299000000317875000
Friday, January 1, 202112349000000282660000
Saturday, January 1, 202215260000000451421000
Sunday, January 1, 202312872000000481871000
Monday, January 1, 202414752000000
Loading chart...

In pursuit of knowledge

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, AbbVie Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. AbbVie, a leader in the industry, has seen its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This reflects its aggressive expansion and investment in marketing and administrative capabilities. In contrast, Sarepta Therapeutics, a smaller player, has increased its SG&A expenses by nearly 900% over the same period, indicating a strategic push to scale operations and enhance market presence. These trends highlight the diverse approaches companies take to balance growth and cost efficiency in a rapidly evolving market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025